Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVES: To evaluate the efficacy of low and medium dose aspirin therapy after coronary surgery by using an indirect comparison meta-analysis. DATA SOURCES: Systematic literature search of Medline, Embase, Cochrane controlled trials register, and trial register sites on the internet. STUDY SELECTION: Outcome was evaluated by angiography and reported as graft occlusion and rate of events in patients. Trials that did not include aspirin as the sole therapy or did not have a placebo control arm were excluded. Articles were assessed for eligibility and quality and grouped according to dosage. The estimated difference in effect of low and medium dose aspirin on graft occlusion was obtained by combining the estimated log relative risks of low dose with placebo and medium dose with placebo. RESULTS: For graft occlusion, the medium dose trials yielded a relative risk reduction of 45% compared with 26% for the low dose trials. The greater effect in the medium dose trials is summarised by a relative risk ratio of 0.74 (95% confidence interval 0.52 to 1.06; P = 0.10) for graft occlusion and 0.81 (0.57 to 1.16; P = 0.25) for events in patients. CONCLUSIONS: Medium dose aspirin may more successfully reduce graft occlusion than low dose regimens within the first year after coronary surgery.

Original publication

DOI

10.1136/bmj.327.7427.1309

Type

Journal article

Journal

BMJ (Clinical research ed.)

Publication Date

12/2003

Volume

327

Addresses

Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge CB3 8RE. eric.lim2@cvsnet.org

Keywords

Humans, Coronary Disease, Graft Occlusion, Vascular, Aspirin, Platelet Aggregation Inhibitors, Postoperative Care, Blood Vessel Prosthesis Implantation, Risk Factors, Randomized Controlled Trials as Topic